| 1366 |
National Cancer Institute |
Html |
en |
Pruritus (PDQ®)–Health Professional Version |
Expert-reviewed information summary about pruritus (itching of the skin) as a complication of cancer or its treatment. Approaches to the management and treatment of pruritus are discussed. |
| pruritus | 0.960641 |
| second-generation antihistamines | 0.585479 |
| skin type | 0.575303 |
| atopic dermatitis | 0.673145 |
| skin surface | 0.599366 |
| worst pruritus | 0.717892 |
| atopic dermatitis population | 0.574946 |
| severe non-dermatological pruritus | 0.718081 |
| skin lipids | 0.573883 |
| Acad Dermatol Venereol | 0.589376 |
| primary dermatitis | 0.600506 |
| significant skin breakdown | 0.59383 |
| blood flow | 0.584198 |
| allergic skin reactions | 0.594569 |
| patients | 0.575543 |
| Dermatol Venereol Leprol | 0.585578 |
| placebo-controlled study | 0.5912 |
| radiation therapy | 0.686843 |
| Int J Dermatol | 0.586614 |
| Pain Symptom Manage | 0.63754 |
| healthy skin | 0.593613 |
| dry skin | 0.639653 |
| neuropathic pruritus | 0.745005 |
| et al. | 0.592668 |
|
| skin cleansing | 0.573636 |
| treatment | 0.596222 |
| skin reactions | 0.599238 |
| Oncol Nurs Forum | 0.699339 |
| skin dermatitis | 0.603221 |
| Opioid-induced Pruritus | 0.704011 |
| skin | 0.704869 |
| uraemic pruritus | 0.705232 |
| PUBMED Abstract | 0.858232 |
| Altered skin integrity | 0.588103 |
| Skin care | 0.624412 |
| Acta Derm Venereol | 0.596823 |
| pruritus relief | 0.700635 |
| itch | 0.57584 |
| allergic contact dermatitis | 0.578553 |
| skin hydration | 0.574125 |
| Clin Exp Dermatol | 0.593566 |
| skin change | 0.583853 |
| aggravates dry skin | 0.598514 |
| chronic idiopathic urticaria | 0.638535 |
| cholestatic pruritus | 0.69774 |
| Dermatol Ther | 0.606265 |
| intractable pruritus | 0.703673 |
| chronic pruritus | 0.736276 |
|
CLICK HERE |
| 1446 |
National Cancer Institute |
Html |
en |
Oral Complications of Chemotherapy and Head/Neck Radiation (PDQ®)–Patient Version |
Expert-reviewed information summary about oral complications, such as mucositis and salivary gland dysfunction, that occur in cancer patients treated with chemotherapy or radiation therapy to the head and neck. |
| cancer treatment | 0.700679 |
| oral mucositis pain | 0.483396 |
| tissue | 0.465551 |
| chemotherapy | 0.631313 |
| blood cell count | 0.467595 |
| mouth problems | 0.466009 |
| PDQ Oral Complications | 0.468892 |
| oral health exam | 0.469677 |
| mouth sores | 0.537291 |
| infections | 0.470414 |
| teeth | 0.49264 |
| neck radiation therapy | 0.476468 |
| high-dose chemotherapy | 0.598756 |
| cancer information summary | 0.466904 |
| oral mucositis | 0.510415 |
| stem cell transplant | 0.72121 |
| oral complications | 0.763758 |
| patients | 0.61166 |
| cancer patients | 0.469036 |
| radiation therapy patients | 0.468456 |
| dry mouth | 0.687045 |
| neck cancers | 0.467921 |
| radiation therapy | 0.972855 |
| Chronic dry mouth | 0.472069 |
| problems | 0.532519 |
|
| regular oral care | 0.496586 |
| oral care | 0.520388 |
| peroxide mouth rinses | 0.475847 |
| PDQ cancer information | 0.50364 |
| head | 0.475462 |
| mucous membranes | 0.503677 |
| mouth moist | 0.469166 |
| patient | 0.472618 |
| taste changes | 0.470678 |
| National Cancer Institute | 0.465975 |
| summary | 0.488366 |
| common oral complications | 0.486948 |
| Wipe mouth | 0.467118 |
| pain | 0.536314 |
| white blood cell | 0.514465 |
| tooth decay | 0.48102 |
| mouth guards | 0.465834 |
| gum disease | 0.504216 |
| salivary glands | 0.547761 |
| Managing Oral Complications | 0.485092 |
| PDQ summary | 0.468583 |
| mouth | 0.82735 |
| Different oral complications | 0.468019 |
| milder oral complications | 0.467906 |
|
CLICK HERE |
| 1628 |
National Cancer Institute |
Html |
en |
Urethral Cancer Treatment (PDQ®)–Patient Version |
Urethral cancer occurs in men and women and can spread quickly to lymph nodes near the urethra. Find out about risk factors, symptoms, tests to diagnose, prognosis, staging, and treatment for urethral cancer. |
| cancer treatment | 0.362333 |
| entire urethra | 0.306444 |
| lymph node dissection | 0.557244 |
| tissue | 0.317299 |
| body | 0.398643 |
| PDQ cancer information | 0.410389 |
| clinical trial search | 0.378188 |
| white blood cells | 0.310278 |
| bladder cancer | 0.308764 |
| clinical trials | 0.773033 |
| nearby lymph nodes | 0.630197 |
| cancer information summary | 0.370147 |
| clinical trial | 0.499273 |
| breast cancer prevention | 0.294123 |
| prostate gland | 0.293841 |
| patients | 0.324988 |
| invasive bladder cancer | 0.301679 |
| treatment clinical trial | 0.300741 |
| NCI PDQ cancer | 0.319347 |
| radiation therapy | 0.651339 |
| Urethral Cancer Treatment | 0.356944 |
| Treatment Editorial Board | 0.30592 |
| urethral cancer | 0.837946 |
| recurrent urethral cancer | 0.334114 |
|
| General information | 0.298754 |
| treatment | 0.543719 |
| new cancer treatments | 0.306575 |
| NCI-supported cancer | 0.322826 |
| cancer cells | 0.450964 |
| proximal urethral cancer | 0.41852 |
| urethral cancer spreads | 0.344537 |
| Cancer Information Service | 0.306473 |
| laser surgery | 0.302658 |
| patient | 0.295185 |
| treatment clinical trials | 0.339398 |
| anterior exenteration | 0.294741 |
| National Cancer Institute | 0.373731 |
| transurethral resection | 0.314195 |
| new treatment | 0.34401 |
| distal urethral cancer | 0.388721 |
| external radiation therapy | 0.308401 |
| cancer research process | 0.298298 |
| cancer clinical trials | 0.402611 |
| cancer information summaries | 0.303961 |
| comprehensive cancer information | 0.304414 |
| internal radiation therapy | 0.302856 |
| cancer | 0.977674 |
| standard treatment | 0.307427 |
|
CLICK HERE |
| 1674 |
National Cancer Institute |
Html |
en |
Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of childhood Langerhans Cell Histiocytosis. |
| Recurrent LCH | 0.49021 |
| cancer treatment | 0.458844 |
| childhood LCH lesions | 0.545029 |
| body | 0.479436 |
| high-risk multisystem LCH | 0.563365 |
| PDQ cancer information | 0.430462 |
| clinical trial search | 0.417075 |
| steroid therapy | 0.417152 |
| LCH lesions | 0.646087 |
| refractory childhood LCH | 0.507141 |
| Refractory LCH | 0.491285 |
| clinical trials | 0.840496 |
| LCH cells | 0.723911 |
| skin-only LCH | 0.533026 |
| cancer information summary | 0.406099 |
| clinical trial | 0.546139 |
| Langerhans cell histiocytosis | 0.451003 |
| patients | 0.432765 |
| LCH | 0.976752 |
| diagnose LCH | 0.533565 |
| lymph nodes | 0.422079 |
| treatment | 0.665224 |
| Progressive LCH | 0.491974 |
| BRAF gene | 0.403636 |
| LCH multisystem disease | 0.521252 |
|
| recurrent childhood LCH | 0.508123 |
| cancer cells | 0.427036 |
| pituitary gland | 0.410888 |
| childhood lch | 0.600077 |
| Adult LCH sections | 0.511455 |
| multisystem lch | 0.599051 |
| LCH trials | 0.499932 |
| LCH treatment | 0.529717 |
| treatment clinical trials | 0.417639 |
| National Cancer Institute | 0.432317 |
| effects cancer treatment | 0.398781 |
| small LCH lesions | 0.540477 |
| new treatment | 0.409482 |
| LCH bone lesions | 0.547532 |
| Adult LCH | 0.522754 |
| body systems | 0.391142 |
| LCH CNS | 0.492291 |
| bone marrow | 0.4649 |
| cancer clinical trials | 0.44841 |
| single-system lch | 0.515862 |
| progressive childhood LCH | 0.507794 |
| childhood LCH skin | 0.522098 |
| cancer | 0.650545 |
| information | 0.432489 |
|
CLICK HERE |
| 1730 |
National Cancer Institute |
Html |
en |
Blood-Forming Stem Cell Transplants |
A fact sheet that explains the step-by-step procedures of two types of transplantations used with high-dose chemotherapy, including their risks and benefits. |
| red blood cells | 0.400014 |
| cancer treatment | 0.26536 |
| cord blood | 0.408194 |
| public cord blood | 0.298389 |
| bone marrow cells | 0.392639 |
| cord blood bank | 0.313292 |
| embryonic stem cells | 0.414015 |
| cord stem cells | 0.382315 |
| healthy cells | 0.309763 |
| bone marrow donation | 0.293131 |
| white blood cells | 0.53145 |
| transplanted stem cells | 0.39836 |
| HLA-matched stem cells | 0.374986 |
| clinical trials | 0.346744 |
| healthy stem cells | 0.372316 |
| stem cells | 0.95315 |
| stem cell transplant | 0.291072 |
| multiple myeloma | 0.26697 |
| Bone marrow aspiration | 0.292859 |
| cord blood banks | 0.343333 |
| immature cells | 0.319355 |
| HLA antigens | 0.259199 |
| appropriate unrelated donor | 0.262231 |
| radiation therapy | 0.329306 |
| transplantation | 0.292216 |
|
| blood-forming stem cells | 0.415789 |
| immature nerve cells | 0.328089 |
| Large volunteer donor | 0.262362 |
| new blood cells | 0.334223 |
| blood stem cell | 0.339528 |
| cancer cells | 0.404042 |
| special blood test | 0.260646 |
| peripheral blood stem | 0.362146 |
| anticancer drugs | 0.263549 |
| donor | 0.356002 |
| PBSCT | 0.299118 |
| patient | 0.341681 |
| marrow’s ability | 0.258871 |
| blood stem cells | 0.413585 |
| healthy bone marrow | 0.302284 |
| umbilical cord blood | 0.366965 |
| umbilical cord | 0.389737 |
| harvested cells | 0.30119 |
| commercial cord blood | 0.270418 |
| Marrow Donor Program® | 0.288844 |
| BMT | 0.322432 |
| bone marrow | 0.850438 |
| autologous transplant | 0.272369 |
| hematopoietic stem cells | 0.478378 |
|
CLICK HERE |
| 1981 |
National Cancer Institute |
Html |
es |
Etapa final de la vida (PDQ®)–Versión para pacientes |
Sumario informativo revisado por expertos sobre el tratamiento y la atención del paciente de cáncer desde los últimos días hasta las últimas horas de vida; esto incluye los síntomas comunes, los dilemas éticos que pueden surgir y la función que desempeña el oncólogo en proveer cuidados al paciente y su familia durante este período. |
| etapa final | 0.952722 |
| alientoLa sensación | 0.303004 |
| siguientes afecciones | 0.302215 |
| Mejor comunicación | 0.301527 |
| posibles daños | 0.30146 |
| Contracciones mioclónicasLas | 0.30427 |
| siguientes tipos | 0.302214 |
| PDQ Aflicción | 0.302895 |
| PDQ Etapa final | 0.30437 |
| suficiente oxÃgeno | 0.302526 |
| HemorragiaLa hemorragia | 0.303897 |
| vÃa rectal | 0.302425 |
| obstructiva crónica | 0.302498 |
| posibles riesgos | 0.304519 |
| efectos directos | 0.302483 |
| vÃas respiratorias | 0.375323 |
| muerteEl estertor | 0.304331 |
| National Cancer Institute | 0.30139 |
| especial cánceres | 0.30221 |
| Mejor alivio | 0.301759 |
| próximas horas | 0.302343 |
|
| Instituto Nacional | 0.302514 |
| PDQ Planificar | 0.312661 |
| contracciones súbitas | 0.303377 |
| pequeñas cantidades | 0.302149 |
| importantes beneficios | 0.301883 |
| cuánta probabilidad | 0.301726 |
| Physician Data Query | 0.305159 |
| LÃquidosLos pacientes | 0.308282 |
| PDQ Fatiga | 0.306846 |
| FatigaLa fatiga | 0.303104 |
| PDQ Delirium | 0.307935 |
| término instrucciones | 0.301507 |
| posibles beneficios | 0.301551 |
| nutrición parenteral | 0.304251 |
| reanimación cardiorrespiratoria | 0.301653 |
| causa sufrimiento | 0.302836 |
| Mejor perspectiva | 0.301742 |
| sufrimiento extremo | 0.306751 |
| numerosos cambios | 0.308661 |
| ReanimaciónLos pacientes | 0.308108 |
|
CLICK HERE |
| 2042 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de vejiga y otros cánceres uroteliales (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca de las pruebas que se usan para detectar sistemáticamente el cáncer de vejiga. |
| Cancer Inst Monogr | 0.315885 |
| Cancer Institute Surveillance | 0.316979 |
| urine cytology | 0.306951 |
| cuadro clÃnico | 0.318123 |
| Cancer Statistics Review | 0.328453 |
| transitional cell carcinoma | 0.316775 |
| Cancer registry problems | 0.313029 |
| Sin embargo | 0.315264 |
| American Cancer Society | 0.340114 |
| Hunt VB | 0.306661 |
| case-control study | 0.305353 |
| bladder cancer | 0.978775 |
| Young TB | 0.311698 |
| Bladder histological changes | 0.316494 |
| undergoing hematuria | 0.308248 |
| Malignant bladder tumors | 0.31586 |
| Can hematuria | 0.308153 |
| risk factors | 0.306901 |
| personas negras | 0.307528 |
| PDQ Exámenes | 0.306867 |
| patients with hematuria | 0.310947 |
| Messing EM | 0.31983 |
| Estados Unidos | 0.311295 |
| Natl Cancer Inst | 0.403227 |
| second cancers | 0.320702 |
|
| screening study using | 0.305437 |
| Bladder Cancer Group | 0.328941 |
| patients with | 0.328907 |
| neuropathic bladder | 0.315447 |
| SEER Cancer Statistics | 0.328432 |
| urinary tract | 0.322774 |
| Urol Clin North | 0.310774 |
| estadio t2+ | 0.30573 |
| detección casero | 0.305242 |
| Occup Med | 0.308003 |
| Cancer Facts | 0.314556 |
| bladder followed | 0.315821 |
| Noone AM | 0.305423 |
| National Cancer Institute | 0.366947 |
| Soloway MS | 0.307825 |
| Epidemiol Biomarkers Prev | 0.327488 |
| cell carcinoma | 0.322375 |
| asymptomatic microhematuria | 0.311534 |
| Clin North Am | 0.316485 |
| cell cytology screening | 0.305294 |
| bladder tumor | 0.350128 |
| invasive bladder | 0.335021 |
| bladder toxicity from | 0.31599 |
| transitional cell | 0.318191 |
|
CLICK HERE |
| 16297 |
National Cancer Institute |
Html |
en |
Medicinal Mushrooms (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the use of medicinal mushrooms as a treatment for people with cancer. |
| G. lucidum products | 0.573204 |
| adjuvant chemotherapy | 0.660268 |
| PSK-treated group | 0.523648 |
| class I–negative patients | 0.557926 |
| control group | 0.693917 |
| humoral immune parameters | 0.519217 |
| Baseline immune parameters | 0.519968 |
| PDQ cancer information | 0.546523 |
| lung cancer | 0.659292 |
| investigators | 0.524722 |
| natural killer | 0.558674 |
| turkey tail | 0.569981 |
| innate immune cells | 0.545469 |
| advanced gastric cancer | 0.572653 |
| doxorubicin -based chemotherapy | 0.54683 |
| patients | 0.832482 |
| cancer patients | 0.665826 |
| G. lucidum | 0.844684 |
| gastric cancer patients | 0.617385 |
| PSK | 0.985645 |
| adjuvant therapy | 0.585553 |
| standard cancer treatments | 0.5637 |
| G. lucidum fruit | 0.543411 |
| cancer patient plasma | 0.523542 |
|
| radiation therapy | 0.5502 |
| lung cancer models | 0.542252 |
| medicinal mushrooms | 0.540839 |
| protein-bound PSK | 0.737238 |
| immune response pathways | 0.537187 |
| lung cancer cohort. | 0.537885 |
| PSK recipients | 0.737199 |
| PSK adjuvant immunotherapy | 0.863333 |
| PSK group | 0.883506 |
| advanced lung cancer | 0.536376 |
| G. lucidum polysaccharides | 0.77527 |
| advanced colorectal cancer | 0.532494 |
| National Cancer Institute | 0.545709 |
| 5-year survival | 0.544251 |
| direct antitumor mechanisms | 0.520707 |
| lung cancer patients | 0.596507 |
| PSK patients | 0.803579 |
| adjuvant PSK | 0.861863 |
| gastric cancer | 0.807983 |
| G. lucidum enhance | 0.535434 |
| direct antitumor | 0.521271 |
| PSK treatment | 0.759609 |
| 5-year survival rates | 0.518116 |
| MHC expression–negative patients | 0.571654 |
|
CLICK HERE |
| 16562 |
National Cancer Institute |
Html |
en |
Screen to Save: NCI Colorectal Cancer Outreach and Screening Initiative |
NCI Colorectal Cancer Outreach and Screening Initiative aims to increase colorectal cancer screening rates among ethnically and racially diverse and rural communities nationwide.
|
| NCI-designated Cancer Centers | 0.680452 |
| country | 0.523395 |
| evidence-based resources | 0.584437 |
| education | 0.537172 |
| National Cancer Advisory | 0.70446 |
| Alaskan Natives | 0.584304 |
| recommendations | 0.526636 |
| overall assessment | 0.573123 |
| ethnically diverse communities | 0.720461 |
| local communities | 0.586899 |
| colorectal screening rates | 0.853048 |
| outreach activities | 0.578711 |
| colorectal cancer screening | 0.850894 |
| rural areas | 0.584762 |
| colorectal cancer | 0.992617 |
| Cancer Control National | 0.675464 |
| PACHE-funded community health | 0.657281 |
| community levels | 0.588626 |
| National Outreach Network | 0.661026 |
| Health Disparities Program | 0.668335 |
| women age | 0.582977 |
| Reduce Cancer Health | 0.704459 |
| American Indians | 0.579831 |
| Colorectal Cancer Awareness | 0.761387 |
|
| Cancer Moonshot | 0.620655 |
| Cancer Health Disparities | 0.821429 |
| NCI Center | 0.608436 |
| Blacks/African Americans | 0.579578 |
| Save initiative | 0.611204 |
| Cancer Health Equity | 0.685373 |
| NCI Colorectal Cancer | 0.830393 |
| Regional Coordinating Directors | 0.639583 |
| diverse partner network | 0.664475 |
| Blue Ribbon Panel | 0.662084 |
| rural communities | 0.646304 |
| Geographic Management | 0.573805 |
| community health educators | 0.957975 |
| outreach efforts | 0.576306 |
| Native Hawaiians | 0.58859 |
| screening resources | 0.639461 |
| Pacific Islanders | 0.584476 |
| evidence-based colorectal cancer | 0.788139 |
| key role | 0.575779 |
| colorectal screening behaviors | 0.792179 |
| NCI-approved colorectal cancer | 0.776303 |
| additional community engagements | 0.645113 |
| Screening Initiative | 0.658551 |
| information | 0.537846 |
|
CLICK HERE |
| 17290 |
National Cancer Institute |
Html |
es |
Uso extraoficial de medicamentos en el tratamiento del cáncer |
Conozca qué es el uso extraoficial o no indicado de medicamentos y el papel que desempeña en el tratamiento del cáncer. |
| régimen r-cvp | 0.716896 |
| régimen cmf | 0.714486 |
| régimen beacopp | 0.710604 |
| amplio uso | 0.781419 |
|
| Estados Unidos | 0.77621 |
| seguro médico | 0.921249 |
| siguientes razones | 0.728265 |
| régimen tac | 0.710628 |
|
CLICK HERE |